- Home
- LMFA vs RDHL Comparison
LMFA vs RDHL Comparison
Compare LMFA & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LMFA | RDHL |
|---|---|---|
| Founded | 2008 | 2009 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3M | 5.6M |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | LMFA | RDHL |
|---|---|---|
| Price | $0.42 | $1.33 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | 496.2K | ★ 1.4M |
| Earning Date | 11-14-2025 | 09-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $7,567,508.00 | ★ $9,550,000.00 |
| Revenue This Year | N/A | $381.91 |
| Revenue Next Year | $22.58 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 157.62 |
| 52 Week Low | $0.40 | $0.91 |
| 52 Week High | $5.14 | $6.77 |
Technical Indicators
Market Signals| Indicator | LMFA | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 33.26 | 55.17 |
| Support Level | $0.40 | $1.29 |
| Resistance Level | $0.46 | $1.39 |
| Average True Range (ATR) | 0.05 | 0.10 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 19.44 | 72.73 |
Price Performance
Historical ComparisonAbout LMFA LM Funding America Inc.
LM Funding America Inc is a financial services company. The company provides funding to nonprofit community associations located in the state of Florida and to nonprofit community associations in the states of Washington and Colorado. Its products include Original Product and New Neighbor Guaranty. Its original product offering consists of providing funding to Associations by purchasing their rights under delinquent accounts that are selected by the Associations arising from unpaid Association assessments. It currently has two lines of business recently commenced cryptocurrency mining business and historical specialty finance business. The Company has two operating segments: Specialty Finance and Mining Operations, which generate the majority of its revenue.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.